Fig 6. Assessment of cancer-patient-derived CARiC9-20/19 CAR-T cells.
T cells derived from healthy donors and cancer patients were nucleofected with CARiC9-20/19. (A) CD8/CD4 ratios were assessed before (PBMC) and after (CAR-T) nucleofection. (B) Distribution of TN, TSCM, TCM, TEM, and TEFF subsets in CD4+ (upper panel) and CD8+ (lower panel) CAR-T cell populations among the patient samples in (A). DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; HL, Hodgkin’s lymphoma; MM, multiple myeloma.